TSG-6 Inhibition in CAF-Rich Tumors to Improve Checkpoint Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Immune checkpoint therapy (ICT) shows poor response in 'cold tumors' like pancreatic ductal carcinoma due to dense stromal compartments and abundant immunesuppressive myeloid cells, hindering effective therapy.

Innovation Solution

Inhibition of TSG-6 secretion by cancer-associated fibroblasts (CAFs) in combination with ICT to enhance therapeutic response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immune checkpoint therapy is administered to treat cold tumors like pancreatic ductal carcinoma, then the therapy is provided to patients, but the therapeutic response is poor due to dense stromal compartments and immunesuppressive myeloid cells

Engineering Contradiction:

Improvetherapeutic responseVSAvoidstromal compartment barrier

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of TSG-6 secretion by CAFs (which creates immunosuppressive microenvironment) into a beneficial target for therapy. By administering anti-TSG-6 antibodies or inhibitors, the harmful TSG-6 protein is neutralized, thereby converting its presence from a therapeutic obstacle into a target that, when blocked, improves immune checkpoint therapy response in cold tumors

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces anti-TSG-6 antibodies or inhibitors as intermediary agents that mediate between the existing immune checkpoint therapy and the tumor microenvironment. These intermediaries specifically bind to TSG-6 secreted by CAFs, blocking its immunosuppressive functions and thereby enabling better penetration and effectiveness of immune checkpoint inhibitors in the tumor

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If TSG-6 is secreted by cancer-associated fibroblasts in the tumor, then the tumor microenvironment becomes immunosuppressive, but immune checkpoint therapy efficacy is reduced

Engineering Contradiction:

Improveimmune checkpoint therapy efficacyVSAvoidimmunosuppressive microenvironment

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts or removes the harmful TSG-6 protein from the tumor microenvironment by introducing anti-TSG-6 antibodies that specifically bind to and sequester TSG-6 secreted by CAFs. This extraction of the harmful factor (TSG-6) from the system eliminates its ability to create immunosuppressive conditions, thereby improving immune checkpoint therapy efficacy

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent converts the harmful immunosuppressive microenvironment created by TSG-6 into a therapeutic opportunity. By targeting and blocking TSG-6 with specific inhibitors or antibodies, the previously harmful condition becomes a target that, when addressed, transforms the microenvironment from immunosuppressive to immunoreactive, enhancing therapy response

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20250377365A1Methods involving detecting TNF stimulated gene 6 (TSG-6) for improving Anti-tumor responses to immune therapy in cancer patients

Publication Date: 2025.12.11 BOARD OF RGT THE UNIV OF TEXAS SYST

AI summary

Aspects herein relate to methods, compositions, and systems directed to the discovery that TSG-6 secretion by cancer-associated fibroblasts (CAFs) in a tumor, in some instances, leads to a poor response to immune checkpoint therapies in the tumor. Inhibition of TSG-6 in certain cancers, in combination with immune checkpoint therapies, led to an improved therapeutic response to the immune checkpoint therapies. Such findings provide methods and compositions for diagnosing, prognosing, and treating certain cancers.